Physician

Allen Randle Beecham, DO

According to 2025 Medicare claims, Allen Beecham, DO (NPI: 1578594057) practices pain management in the Marietta, GA market, with the plurality of this provider's patient population coming from Cobb, GA. This provider's primary affiliated billing organization is GEORGIA PHYSICIAN ASSOCIATES, PC (NPI: 1528496353; TIN: 46-3348859) and primary practice location at 30114-9998.

Beecham's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 348 traditional Medicare patients, billed 6,846 HCPCS/CPT codes, and received $512,215 in Medicare payments. The top billing code was G0483 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 10,506 prescription claims across 391 beneficiaries totaling $739,764 in drug costs, led by Relistor (Methylnaltrexone Bromide). 2018 DME data shows 12 claims. Open Payments data shows 42 records totaling $611. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $1,216,596 to $512,215. In contrast, Part D prescription costs have moved sharply higher in recent years, from $351,220 to $739,764. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	514	64,508	$1,216,596
2016	443	10,464	$700,163
2017	487	10,212	$812,724
2018	458	6,618	$657,205
2019	440	4,751	$491,862
2020	409	5,857	$628,570
2021	372	5,449	$610,016
2022	309	5,089	$532,950
2023	349	4,719	$500,847
2024	348	6,846	$512,215

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	418	5,801	$351,220
2016	331	6,128	$412,339
2017	337	3,473	$269,669
2018	414	4,195	$303,982
2019	426	4,256	$350,333
2020	399	7,526	$518,747
2021	441	8,678	$740,826
2022	406	10,786	$965,667
2023	430	10,799	$955,886
2024	391	10,506	$739,764

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	13	$13,353
2016	37	37	$37,851
2017	N/R	N/R	N/R
2018	12	12	$12,498
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	315	918	$237
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	253	1,176	$110
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	40	60	$82
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	143	1,288	$61
80307	Testing for presence of drug, by chemistry analyzers	167	1,200	$60

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Relistor	Methylnaltrexone Bromide	70	2,204	$172,070
Xtampza Er	Oxycodone Myristate	334	9,205	$133,765
Movantik	Naloxegol Oxalate	142	4,298	$58,346
Oxycontin	Oxycodone Hcl	70	1,901	$54,060
Oxycodone Hcl	Oxycodone Hcl	1,912	51,850	$50,059

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	42	$611	Virtus Pharmaceuticals LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Allen Randle Beecham, DO?

Tedicare shows public-source Medicare data for Allen Randle Beecham, DO (NPI 1578594057), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Allen Randle Beecham, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Allen Randle Beecham, DO?

Allen Randle Beecham, DO is linked to GEORGIA PHYSICIAN ASSOCIATES, PC (billing NPI 1528496353) in the available physician profile data.

Does Allen Randle Beecham, DO have Open Payments data?

Allen Randle Beecham, DO has 42 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.